General Information of Drug Off-Target (DOT) (ID: OTF9T8I2)

DOT Name DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F)
Synonyms RNA polymerases I, II, and III subunit ABC2; DNA-directed RNA polymerase II subunit F; DNA-directed RNA polymerases I, II, and III 14.4 kDa polypeptide; RPABC14.4; RPB14.4; RPB6 homolog; RPC15
Gene Name POLR2F
Related Disease
Glioblastoma multiforme ( )
Advanced cancer ( )
Carcinoma ( )
Colorectal carcinoma ( )
Colorectal neoplasm ( )
Waardenburg syndrome type 2A ( )
UniProt ID
RPAB2_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1QKL ; 5IY6 ; 5IY7 ; 5IY8 ; 5IY9 ; 5IYA ; 5IYB ; 5IYC ; 5IYD ; 6DRD ; 6O9L ; 6XRE ; 7A6H ; 7AE1 ; 7AE3 ; 7AEA ; 7AST ; 7D58 ; 7D59 ; 7DN3 ; 7DTH ; 7DTI ; 7DU2 ; 7FJI ; 7FJJ ; 7LBM ; 7OB9 ; 7OBA ; 7OBB ; 7VBA ; 7VBB ; 7VBC ; 8A43 ; 8ITY ; 8IUE ; 8IUH
Pfam ID
PF01192
Sequence
MSDNEDNFDGDDFDDVEEDEGLDDLENAEEEGQENVEILPSGERPQANQKRITTPYMTKY
ERARVLGTRALQIAMCAPVMVELEGETDPLLIAMKELKARKIPIIIRRYLPDGSYEDWGV
DELIITD
Function
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Common component of RNA polymerases I, II, and III which synthesize ribosomal RNA precursors, mRNA precursors and many functional non-coding RNAs, and small RNAs, such as 5S rRNA and tRNAs, respectively. Pol II is the central component of the basal RNA polymerase II transcription machinery. Pols are composed of mobile elements that move relative to each other. In Pol II, POLR2F/RPABC2 is part of the clamp element and together with parts of POLR2A/RPB1 and POLR2B/RPB2 forms a pocket to which the POLR2D/RPB4-POLR2G/RPB7 subcomplex binds.
KEGG Pathway
R. polymerase (hsa03020 )
Nucleotide excision repair (hsa03420 )
Cytosolic D.-sensing pathway (hsa04623 )
Huntington disease (hsa05016 )
Reactome Pathway
Formation of the Early Elongation Complex (R-HSA-113418 )
Formation of HIV elongation complex in the absence of HIV Tat (R-HSA-167152 )
Formation of the HIV-1 Early Elongation Complex (R-HSA-167158 )
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection (R-HSA-167160 )
HIV Transcription Initiation (R-HSA-167161 )
RNA Polymerase II HIV Promoter Escape (R-HSA-167162 )
Transcription of the HIV genome (R-HSA-167172 )
Formation of HIV-1 elongation complex containing HIV-1 Tat (R-HSA-167200 )
Pausing and recovery of Tat-mediated HIV elongation (R-HSA-167238 )
Abortive elongation of HIV-1 transcript in the absence of Tat (R-HSA-167242 )
Tat-mediated HIV elongation arrest and recovery (R-HSA-167243 )
Tat-mediated elongation of the HIV-1 transcript (R-HSA-167246 )
HIV elongation arrest and recovery (R-HSA-167287 )
Pausing and recovery of HIV elongation (R-HSA-167290 )
Viral Messenger RNA Synthesis (R-HSA-168325 )
Cytosolic sensors of pathogen-associated DNA (R-HSA-1834949 )
MicroRNA (miRNA) biogenesis (R-HSA-203927 )
NoRC negatively regulates rRNA expression (R-HSA-427413 )
B-WICH complex positively regulates rRNA expression (R-HSA-5250924 )
Transcriptional regulation by small RNAs (R-HSA-5578749 )
PIWI-interacting RNA (piRNA) biogenesis (R-HSA-5601884 )
Activation of anterior HOX genes in hindbrain development during early embryogenesis (R-HSA-5617472 )
RNA Polymerase II Pre-transcription Events (R-HSA-674695 )
Formation of TC-NER Pre-Incision Complex (R-HSA-6781823 )
Transcription-Coupled Nucleotide Excision Repair (TC-NER) (R-HSA-6781827 )
Dual incision in TC-NER (R-HSA-6782135 )
Gap-filling DNA repair synthesis and ligation in TC-NER (R-HSA-6782210 )
TP53 Regulates Transcription of DNA Repair Genes (R-HSA-6796648 )
FGFR2 alternative splicing (R-HSA-6803529 )
RNA polymerase II transcribes snRNA genes (R-HSA-6807505 )
mRNA Capping (R-HSA-72086 )
mRNA Splicing - Major Pathway (R-HSA-72163 )
mRNA Splicing - Minor Pathway (R-HSA-72165 )
Processing of Capped Intron-Containing Pre-mRNA (R-HSA-72203 )
RNA Polymerase I Transcription Initiation (R-HSA-73762 )
RNA Polymerase I Promoter Escape (R-HSA-73772 )
RNA Polymerase II Promoter Escape (R-HSA-73776 )
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening (R-HSA-73779 )
RNA Polymerase III Chain Elongation (R-HSA-73780 )
RNA Polymerase I Transcription Termination (R-HSA-73863 )
RNA Polymerase III Transcription Termination (R-HSA-73980 )
RNA Polymerase III Abortive And Retractive Initiation (R-HSA-749476 )
RNA Polymerase II Transcription Initiation (R-HSA-75953 )
RNA Polymerase II Transcription Elongation (R-HSA-75955 )
RNA Polymerase II Transcription Initiation And Promoter Clearance (R-HSA-76042 )
RNA Polymerase III Transcription Initiation From Type 1 Promoter (R-HSA-76061 )
RNA Polymerase III Transcription Initiation From Type 2 Promoter (R-HSA-76066 )
RNA Polymerase III Transcription Initiation From Type 3 Promoter (R-HSA-76071 )
RNA Pol II CTD phosphorylation and interaction with CE (R-HSA-77075 )
Signaling by FGFR2 IIIa TM (R-HSA-8851708 )
Estrogen-dependent gene expression (R-HSA-9018519 )
Inhibition of DNA recombination at telomere (R-HSA-9670095 )
Formation of RNA Pol II elongation complex (R-HSA-112382 )

Molecular Interaction Atlas (MIA) of This DOT

6 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Glioblastoma multiforme DISK8246 Strong Altered Expression [1]
Advanced cancer DISAT1Z9 Limited Biomarker [2]
Carcinoma DISH9F1N Limited Altered Expression [2]
Colorectal carcinoma DIS5PYL0 Limited Altered Expression [2]
Colorectal neoplasm DISR1UCN Limited Altered Expression [2]
Waardenburg syndrome type 2A DISM4IVI Limited Genetic Variation [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
8 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [4]
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [5]
Tretinoin DM49DUI Approved Tretinoin decreases the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [6]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [7]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide decreases the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [6]
Carbamazepine DMZOLBI Approved Carbamazepine affects the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [8]
Diclofenac DMPIHLS Approved Diclofenac affects the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [8]
chloropicrin DMSGBQA Investigative chloropicrin decreases the expression of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene affects the methylation of DNA-directed RNA polymerases I, II, and III subunit RPABC2 (POLR2F). [9]
------------------------------------------------------------------------------------

References

1 Primary glioblastoma transcriptome data analysis for screening survival-related genes.J Cell Biochem. 2020 Feb;121(2):1901-1910. doi: 10.1002/jcb.29425. Epub 2019 Oct 21.
2 POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?.Anticancer Res. 2008 Mar-Apr;28(2B):1221-7.
3 Waardenburg syndrome: Novel mutations in a large Brazilian sample.Eur J Med Genet. 2018 Jun;61(6):348-354. doi: 10.1016/j.ejmg.2018.01.012. Epub 2018 Jan 31.
4 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
5 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
6 Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
7 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
8 Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
9 Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
10 Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.